Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
RESEARCH TOOLSreports
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.50 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)45.87K
Market Cap
C$85.48M
Enterprise ValueC$130.64M
Total Cash (Recent Filing)$576.32K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)13.3
Beta1.04
Next Earnings
Jul 01, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding32,258,354
10 Day Avg. Volume23,442
30 Day Avg. Volume45,867
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda7.07
Forecast
1Y Price Target
C$8.00Price Target Upside173.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Secures Public Reimbursement for Trecondyv® in Quebec
PremiumCompany Announcements
Medexus Reports Strong Initial Uptake of GRAFAPEX™ in U.S. Market
PremiumCompany Announcements
Medexus Returns Gleolan U.S. Rights to NX Development Corp.
PremiumCompany Announcements
Medexus Launches GRAFAPEX in US, Eyes $100M Revenue
PremiumCompany Announcements
Medexus Pharmaceuticals: Robust Earnings Amidst Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMedexus's FQ3 results were ahead of initial estimates, showing strong performance.
Regulatory ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.
Bears Say
Generic RiskThere is generic risk in the base business with Rupall losing exclusivity.
Pricing AssumptionsInitial pricing assumptions for GRAFAPEX appear optimistic.
Regulatory SetbackMedexus faces a negative Health Canada setback for Terbinafine.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.36% Insiders
0.38%
Mutual Funds
0.03% Other Institutional Investors
92.23% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.50 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$85.48M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jul 01, 2025 which is in 51 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 05, 2025. The company reported C$0.041 earnings per share for the quarter, missing the consensus estimate of C$0.05 by -C$0.008.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -0.09.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 32,258,354 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0.041 in its last earnings report, missing expectations of C$0.05. Following the earnings report the stock price went down -19.525%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$8.00 (173.97% Upside)
C$8.00 (173.97% Upside)
Insider Transactions
Bought Shares
Worth C$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.56%
12-Months-Change
Fundamentals
Return on Equity
11.27%
Trailing 12-Months
Asset Growth
-0.72%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
---
MDP Stock 12 Month Forecast
Average Price Target
C$8.00
▲(173.97% Upside)
Technical Analysis
Aequus Pharmaceuticals
―
West Island Brands Inc
―
Medicure
―
Biosyent
―
OrganiGram Holdings
―
---